Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha...

Related Keywords

Washington ,United States ,Kevin Moran ,Vanda Pharmaceuticals Inc ,Twitter ,Community Sample ,Prnewswire Vanda Pharmaceuticals Inc ,Novartis ,International Journal Of Virtual Reality ,Exchange Commission ,Head Of Corporate Affairs ,Trier Social Stress Test ,Subjective Units ,Distress Scale ,Gender Differences ,Stress Responses ,Virtual Reality Trier Social Stress ,International Journal ,Virtual Reality ,Public Speaking Fears ,Psychological Interventions ,Public Speaking ,Note Regarding Forward Looking ,Financial Condition ,Annual Report ,Quarterly Reports ,Current Reports ,Vice President ,Chief Financial Officer ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Mental Health ,Clinical Trials Amp Medical Discoveries ,